lazabemide

04/01/1994 - "No significant improvement in the clinical features of Parkinson's disease was found after 4 weeks of lazabemide treatment. "
11/01/1999 - "To evaluate whether lazabemide has proarrhythmic or hypotensive potency in Parkinson's disease (PD), we conducted an 8-week, double-blind, placcbo-controlled, parallel group study with use of 24-hour ambulatory electrocardiographic (ECG) monitoring. "
07/01/1996 - "We previously found lazabemide to be safe and well tolerated at dosages of up to 400 mg/day during a 6-week study of 201 patients with early untreated Parkinson's disease (PD). "
04/01/1993 - "A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. "
07/01/1996 - "Effect of lazabemide on the progression of disability in early Parkinson's disease. "

04/01/1993 - "The overall safety and benefits of lazabemide observed in this short-term study justify further long-term investigations to determine if this monoamine oxidase type B inhibitor can slow the clinical progression of Parkinson's disease."

11/01/2000 - "The present study investigated the effect of postischaemic infusion of an irreversible monoamine oxidase B (MAO-B) inhibitor, l-deprenyl, an equipotent dose of a reversible MAO-B inhibitor, lazabemide, or 0.9% NaCl on infarct volumes following focal cerebral ischaemia in rats. "

11/01/1999 - "Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease."

01/01/1999 - "Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives."
09/01/1994 - "We conclude that enzyme radioautography with [3H]lazabemide is a reliable high resolution assay for plaque-associated astroglioses in Alzheimer's disease. "
09/01/1994 - "Lazabemide, a selective reversible monoamine oxidase B inhibitor, is currently under clinical evaluation for the treatment of Parkinson's and Alzheimer's diseases. "